^
Association details:
| Biomarker: | SDHB mutation + NF1 mutation |
|---|---|
| Cancer: | Gastrointestinal Stromal Tumor |
| Drug: | DS-6157 (Topoisomerase I inhibitor, GPR20 -targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase 1, multicenter, open-label, first-in-human study of DS-6157a in patients (pts) with advanced gastrointestinal stromal tumor (GIST).
Published date:
05/26/2022
Excerpt:
One pt with SDH-deficient GIST with both SDH B and NF1 mutations, had a confirmed PR with shrinkage of -75%; 18 pts (53%) experienced stable disease and 10 pts (29%) experienced progressive disease as best response. Median progression-free survival across all dose levels was 3.6 months (95% CI, 1.6, 6.9)....DS-6157a was generally well tolerated with early signs of moderate clinical activity.
DOI:
10.1200/JCO.2022.40.16_suppl.11512
Trial ID:
